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Human embryonic, induced pluripotent, and adult stem
cells are invaluable tools for drug discovery, human
toxicology, and studies on human development. Through
controlled stem cell differentiation, large quantities of
cell types from various tissues have been generated,
including lung, liver, intestine, and neural to name a few
(Lancaster et al., 2013; Spence et al., 2011; Takebe et al.,
2013; Wetsel et al., 2011). In all cases, expansion in a
stem or progenitor cell state is required to achieve large
cell numbers, followed by differentiation into terminally
differentiated fates. Such expansion and differentiation
processes depend on myriad soluble factors, and cellular
interactions with other cells and the extracellular matrix
(ECM). This complexity has motivated the development
of high-throughput screening tools to explore the large
combinatorial signaling ‘‘space’’ associated with stem
cell differentiation. The development of high-throughput
screening platforms that emulate the complexity of natural
stem cell microenvironments has provided basic insights
into stem cell regulation, as well as enabling numerous
applications (Lutolf et al., 2009; Soen et al., 2006). For
example, toxicity screening systems that use human
stem/progenitor cells and their terminally differenti-
ated derivatives may help improve preclinical charac-
terization of drug candidates and thereby reduce the
extremely high attrition rates that plague drug develop-
ment, often due to unforeseen toxicity (Hay et al., 2014;
Ledford, 2011).
Cell-based microarrays have been used to screen for the
effects of arrayed ECM proteins on neural stem cell prolif-
eration and differentiation (Soen et al., 2006). The exper-
imental platforms for these cell-based studies, however,970 Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016 j ª 2016 The
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(2D) environments, despite the fact that three-dimen-
sional (3D) approaches have gained increasing interest
(Ranga et al., 2014). In particular, 3D culture models
may better mimic the in vivo cellular microenvironment,
which can be critical in phenotypic screens (Barcellos-
Hoff et al., 1989; Yarmush and King, 2009). However,
challenges remain in developing and implementing mi-
croarray-based 3D systems for screening purposes,
including developing stable natural or synthetic matrices
that enable rapid diffusion of soluble factors and re-
agents for 3D-based studies (Li et al., 2014; Ranga et al.,
2014; Yarmush and King, 2009). Furthermore, samples ar-
rayed on a surface often share the same culture medium,
whereas it would be desirable to screen many liquid media
compositions using a 3D culture platform. To address
these limitations, we developed a microfabricated plastic
‘‘chip’’ system capable of 3D cell culture at the nanoliter
scale. This platform, which has been described previously
for rapid toxicity screening of compounds with human
hepatocellular carcinoma cells, consists of two comple-
mentary chips that ‘‘stamp’’ together to generate up to
532 independent microscale cultures per chip (Kwon
et al., 2014).
In the current work, we use this chip-based microarray
platform to culture and perform high-content screening
of a human neural progenitor cell (NPC) line, ReNcell
VM, in 3D microscale cultures encapsulated within Matri-
gel. The NPCs were maintained in their multipotent state
or induced to differentiate, and the resultant cultures
were used to quantify expression of key cellular proteins,
screen for acute toxicity and anti-proliferative effects of a
diverse range of biologically active compounds, and inves-
tigate whether variable toxic sensitivities exist betweenAuthor(s).
ns.org/licenses/by/4.0/).
Figure 1. Microarray Chip Platform
The platform consists of two complementary polystyrene microchips measuring 253 75 mm, each containing 532 micropillars (PillarChip)
or microwells (WellChip) arranged in a 14 3 38 array. The feature-to-feature distance of pillars and wells is 1.5 mm with diameters of
750 mm and 1.2 mm, respectively. Cell spots consist of Matrigel-encapsulated cells spotted as 100 nL cultures atop micropillars and the
microwells contain 850 nL of medium. Medium change is straightforward and consists of lifting a PillarChip from one WellChip and
stamping into another containing fresh medium. Fluorescence-based endpoint assays are used to measure viability, proliferation, and
protein expression of on-chip cultures.undifferentiated and differentiating cells. Such informa-
tion provides new insight into how miniaturization of 3D
cell culture impacts NPC proliferation and differentiation
for use in high-content, high-throughput screening of
toxicity and cell phenotype.RESULTS
Characterization of 3D Microarray NPC Cultures
The microarray chip platform consists of two comple-
mentary polystyrene microchips with 532 micropillars
(PillarChip) or microwells (WellChip). Cells are encapsu-
lated in a 3D matrix atop a PillarChip, which is submerged
into a WellChip for on-chip culture (Figure 1). In general,
3D cultures require cumbersome imaging and analytical
techniques (e.g., confocal imaging and stack reconstruc-
tion) (Li et al., 2015). To simplify this process, on-chip 3D
cultures were rapidly dried for image processing and anal-
ysis; however, for samples labeled with fluorescent live-
cell stains, this resulted in cell lysis. It was reasoned thiscell lysis could be prevented with a lyoprotectant, and
addition of 50 mM trehalose to the Dulbecco’s phos-
phate-buffered saline (DPBS) wash solution prior to drying
indeed preserved cytoplasmic staining of calcein, enabling
the simplified imaging approach (Figure S1A).
The sensitivity of fluorescent live-cell stains to assess
quantitatively cell spots was determined using on-chip cul-
tures prepared with a range of cell densities (up to 1 3 107
cells/mL). As anticipated, we observed a near-linear rela-
tionship between fluorescence intensity and seeding den-
sity for calcein and Hoechst 33342, which demonstrated
that the fluorescence intensities are representative of living
and total cells, respectively, within the 3D on-chip cul-
tures (Figures 2A–2C). Single-cell analysis revealed on-
chip post-printing viability of NPC cultures to be 84% ±
5% and 80% ± 6% (mean ± SD, n = 396 biological repli-
cates) in 0.5% and 1% Matrigel, respectively, at 300 cells
per spot (Figure S1B). ReNcell VM, the human NPC line
used in this study, is a commercially available, v-myc
immortalized region-specific human neural progenitor
cell line derived from ventral mesencephalon bulk tissueStem Cell Reports j Vol. 7 j 970–982 j November 8, 2016 971
Figure 2. On-Chip Viability Assay Sensitivity and On-Chip NPC Culture Characterization
(A–C) Representative fluorescence images of assayed cell spots, seeded with up to 1 3 107 cells/spot in 0.5% or 1% Matrigel (A). The
background adjusted mean fluorescence intensity ± SEM (n = 72 biological replicates) is plotted against seeding density in both (C) 0.5%
and (:) 1% (w/v) Matrigel for calcein (B) and Hoechst 33342 (C).
(D and E) Phase contrast (D) and z stack (E) reconstructed confocal images of NPCs cultured on-chip in 0.5% (i) and 1% (ii) Matrigel for
3 days.
(F) Growth assessed by calcein staining intensity is qualitatively apparent in fluorescent image montages (compiled with Cellomics
software) when comparing staining between on-chip cultures after 1 (i) and 7 (ii) days of culture.
(G) Quantified calcein intensity of ReNcell VM NPCs cultured on-chip in (-) 0.5% and (C) 1% Matrigel over time (one time-lapse
experiment, where each point represents the mean ± SEM of 396 biological replicates). Scale bars, 300 mm.dissections of a 10-week fetus (Donato et al., 2007). Ar-
rayed, undifferentiated NPCs encapsulated in Matrigel
(0.5% and 1% [w/v]) had a compact cylindrical/spherical
shape (Figure 2D), notably different from their spread
and flattened appearance in 2D monolayer cultures (Fig-
ure S1C). Calcein staining indicated that the cells were
uniformly distributed throughout the cell spots, and the
estimated average spot height (n = 3 biological replicates)
was 250 ± 17 mmand 204 ± 5 mm for 0.5% and 1%Matrigel,
respectively (Figure 2E).972 Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016The effects of encapsulating and soluble Matrigel con-
centration, fibroblast growth factor 2 (FGF2) and epidermal
growth factor (EGF) concentrations, seeding density, and
frequency ofmedium changewere screened in a 25 factorial
design experiment, which revealed daily medium change
had a significant impact on growth and viability on-chip,
and was thus employed in subsequent experiments (Fig-
ure S2). The concentration of EGF and FGF2, and soluble
or encapsulating Matrigel, had statistically insignificant
effects on cell viability and growth. In addition, cultures
seeded at 500 cells/spot had a significantly higher calcein
fluorescence than those seeded at 300 cells/spot, which
demonstrated that the cultures remained viable at higher
cell densities.
The effect of culture time on NPC proliferation when
cultured within Matrigel on-chip was measured in a time-
lapse experiment. Four on-chip cultures were prepared
with either 0.5% or 1% Matrigel, and viability across an
entire chip wasmeasured after 1, 3, 5, and 7 days of culture.
As anticipated, calcein fluorescence intensity per spot
increased over time (Figures 2F and 2G). NPCs cultured
on-chip experienced a lag phase (1–2 days) followed by
growth with calculated cell doubling times of 67 and
70 hr for 0.5% and 1%Matrigel, respectively. Ultimately,
1% Matrigel encapsulation resulted in increased phys-
ical stability of cell spots and was used for subsequent
screening.
Protein Expression of NPCs in 3D Microscale Cultures
On-Chip
Several proteins associated with the maintenance and/or
function of various cell states were used as markers to
characterize undifferentiated and differentiated NPC phe-
notypes. Undifferentiated NPCs express the intermediate
filament Nestin (NES) and transcription factor SOX2
(Komitova and Eriksson, 2004; Park et al., 2010), and can
express additional markers such as glial fibrillary acidic
protein (GFAP), an intermediate filament also expressed
in terminally differentiated astrocytes (Goldman, 2003).
Differentiating NPCs begin to express proteins associated
with specific terminal lineages, e.g., astrocyte differentia-
tion can be characterized by increased expression of
GFAP and S100b, a regulatory calcium-binding protein
(Bignami et al., 1972; Markiewicz and Lukomska, 2006;
Raponi et al., 2007). Analogously, progenitor cells differ-
entiating into neurons transiently express doublecortin
(DCX), a microtubule-associated protein, before terminal
differentiation and expression of bIII tubulin (TUBB3), a
microtubule protein (Couillard-Despres et al., 2006; Ros-
kams et al., 1998). Cells differentiating into oligoden-
drocytes express CNPase (CNP), an enzyme involved in
myelination (Sprinkle, 1989).
Withdrawal of EGF and FGF2 from culture medium is
expected to induce differentiation of ReNcell VM, during
which time the stem/progenitor cells experience signifi-
cant changes inmorphology, protein expression, and func-
tion to develop into terminally differentiated phenotypes
(Donato et al., 2007; Sun et al., 2008). Immunofluorescence
characterization of protein markers associated with undif-
ferentiated and differentiated cell states before and after in-
duction of differentiation has, to our knowledge, not been
donewith this cell line. Thus, we proceeded to assess differ-
entiation induced by EGF and FGF2 withdrawal using bothimmunofluorescence and western blot analysis. To address
antibody quality, primary antibodies were validated using
human cell lines to verify specificity for immunofluores-
cence (Figures S3A–S3D).
ReNcell VM cultured as monolayers (2D) or embedded
within 1% Matrigel (3D) were cultured with and without
EGF and FGF2 to assess protein expression. For undiffer-
entiated 2D cultures (+EGF/FGF2), expression of DCX,
TUBB3, GFAP, SOX2, and NES was detected by both west-
ern analysis (Figure 3A) and immunofluorescence (Fig-
ure 3E). Differentiation induced through removal of EGF
and FGF2 for 10 days resulted in drastic morphological
changes (Figure S1C). Western analysis revealed that
the loading control-relative expression of TUBB3, GFAP,
and CNP increased while, unexpectedly, the expression of
NES and SOX2 persisted (Figure 3A). A second SOX2 anti-
body was used in a repeat experiment to account for the
possibility of a non-specific signal, yielding a similar result
(Figure 3B). Notably, 2D differentiation for 6 weeks resulted
in substantial SOX2 downregulation (Figure 3C). Immuno-
fluorescence analysis revealed that differentiating ReNcell
VM continued to express SOX2, NES, DCX, and GFAP
while the number of cells expressing TUBB3 increased (Fig-
ure 3F) after 10 days. S100b and CNP expression was unde-
tected in 2D cultures by immunofluorescence (data not
shown). Western analysis of 3D slab cultures revealed an
increase in relative expression of TUBB3 and GFAP after
culture without EGF and FGF2 (Figure 3D), similar to 2D.
However, there were also notable differences between
monolayer and 3D slab differentiation. Specifically, in the
3D slab cultures CNP was undetected, and there was an in-
crease in relative expression of SOX2 and NES after 10 days
without EGF and FGF2.
Analysis of protein expression on-chipwas performed us-
ing a modified in-cell, on-chip immunofluorescence assay.
Sensitivity of the assay was first determined by spotting un-
differentiated NPCs at varied cell densities (1, 2.5, and 5 3
106 cells/mL) in 1% Matrigel followed by immunofluores-
cence-based detection of NES and GFAP. As anticipated,
the total fluorescence intensity of each marker increased
with spotting cell density (Figure S3E). Dividing immuno-
fluorescence intensity by Hoechst 33342 intensity within
each spot resulted in similar normalized values for all
seeding densities (Figure S3F), suggesting that Hoechst
33342 intensity normalization accounts for differences in
cell number when analyzing protein expression on-chip.
Expression of protein markers indicative of cell fate was
then quantified on-chip after a 5-day culture with EGF
and FGF2 and again after 10 subsequent days without
EGF and FGF2 to induce differentiation. Undifferentiated
cultures (+EGF/FGF2) expressed SOX2, NES, GFAP, and
DCX after culture on-chip (Figure 4A). Differentiation
(EGF/FGF2) resulted in growth of cell extensions,Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016 973
Figure 3. Off-Chip Analysis of ReNcell VM
NPC Protein Expression in 2D Monolayer
and 3D Matrigel Cultures
(A) Western blot analysis of fate-specific
protein markers in ReNcell VM 2D monolayer
cultures before and after a 10-day culture
without EGF and FGF2 to induce differenti-
ation.
(B) SOX2 western blot analysis in a 2D
monolayer culture with an additional anti-
body specific for SOX2 (Cell Signaling
Technologies).
(C) SOX2 western blot analysis in 2D
monolayer culture following a 6-week
differentiation.
(D–F) Western blot analysis of ReNcell VM
cultured off-chip in 3D 1% Matrigel before
and after growth factor withdrawal (D).
Immunofluorescence analysis of undiffer-
entiated (+EGF/FGF2) (E) and differenti-
ating (EGF/FGF2). (F) ReNcell VM cultured
in 2D monolayer. Merged fluorescence im-
ages of the indicated protein and Hoechst
33342 (used as a counterstain) are depicted
with the exception of SOX2 (nuclear stain-
ing), where the Hoechst 33342 nuclei were
used to create an overlay mask. Brightness
and contrast of single-channel images were
adjusted with ImageJ to eliminate back-
ground using samples stained with fluores-
cent secondary antibody only prior to
merging. GAPDH and vinculin were used as
loading controls. Scale bars, 100 mm.depicted in the immunofluorescence images of GFAP and
NES (Figure 4B). Expression of SOX2 persisted while NES,
TUBB3, GFAP, S100b, and DCX expression increased (p <
0.05, two-tailed t test; Figure 4A) in differentiating cultures.
Taken together, these results suggest that while EGF
and FGF2 withdrawal is sufficient for inducing increased
expression of terminal markers, the extent of differentia-
tion is moderate after only 10 days. Nonetheless, the
changes in protein expression support the conclusion the
NPCs cultured without EGF and FGF2 are in the process of
differentiating into primarily pan-astrocytic and neuronal
lineages.
Acute Toxicity Screening of NPCs in 3D Microarray
Cultures
To demonstrate the high-throughput screening capability
of the chip platform, we evaluated the dose-response ef-
fects on cell viability of a 24-compound library with diverse
structural and biological properties, consisting of approved974 Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016drugs, heavy metals, and pesticides, some of which are re-
garded as acutely neurotoxic (Table S2). Cell proliferation
was then tested for a subset of this library. For both viability
and proliferation, the effect of the compounds was tested
on both undifferentiated and differentiating NPC cultures,
whichwould uncover cell-state specific (self-renewal versus
differentiation) differences in toxicity.
On-chip cultures of undifferentiated and 10-day differen-
tiated NPCs were stamped with WellChips filled with
compound-containing solutions and incubated for 72 hr
prior to viability assessment. Vehicle-control normalized
viabilities were plotted against compound concentration
to generate dose-response plots (Figures 5A and S4). The
acute viability screen identified 16 compounds that
substantially decreased viability (R50% killing) relative
to controls (Table S3). The dose-response data for nine
of these compounds were suitable for sigmoidal curve
fitting and calculation of a median inhibitory concen-
tration (IC50) value (Table 1). The sigmoidal fits for
Figure 4. On-Chip Analysis of ReNcell VM NPC Protein Expression in Microscale 3D Matrigel Cultures
(A) Hoechst 33342-normalized immunofluorescence detection of cell fate-specific protein markers within on-chip NPC cultures before and
after a 10-day culture without EGF and FGF2. Mean ± SEM plotted for 36 independent biological replicates per marker for each condition.
*p < 0.05 (two-tailed Student’s t test) indicates the difference between undifferentiated and differentiating cultures.
(B) Representative images of immunofluorescence stained on-chip NPC cultures before and after a 10-day culture without EGF and FGF2
(green or red); Hoechst 33342-counterstained nuclei (blue). The Cellomics analysis suite was used for single-channel brightness and
contrast adjustment to eliminate background signals as determined from samples stained only with fluorescently labeled secondary
antibody. Scale bars, 300 mm.undifferentiated and differentiating NPCs were compared
to assess whether differential sensitivities (i.e., different
IC50 values) existed for the screened compounds. Statisti-
cally significant (p < 0.05, two-tailed t test) IC50 values
were observed between undifferentiated and differenti-
ating cultures for retinoic acid, doxorubicin (DOX), 5-fluo-
rouracil (5-FU), pitavastatin, and acetaminophen. In
addition, the IC50 values in response to cytosine arabino-
side (CA) were notably different, although the statistical
difference warranted further investigation (p < 0.10, two-
tailed t test). The resulting differences in viability between
undifferentiated and differentiating cultures in response to
pitavastatin and 5-FU (Figures 5A and S4) was particularly
interesting, with substantially greater killing of undifferen-
tiated cultures for these compounds.
Differential toxic effects could be explained, in part, as
a consequence of the different proliferative states be-tween the undifferentiated and differentiating NPCs. To
this end, the thymidine analog, 5-ethynyl-20-deoxyuri-
dine (EdU), was used to detect actively proliferating cells
on-chip following exposure to compounds or vehicle
control to determine dose-response effects on prolifera-
tion (Figures 5B and S5), and sigmoidal curves were
fit, when appropriate, to obtain IC50 values (Table 1).
We found 60% of undifferentiated NPCs incorporated
EdU over a 24-hr period as opposed to 3% of differenti-
ating cultures. Following exposure to 5-FU, a known anti-
proliferative agent, we observed a sharp decrease to no
EdU incorporation in both undifferentiated and differen-
tiating NPC cultures. In consideration with the differen-
tial cytotoxicity induced by 5-FU, this result confirms
the different proliferation rates of undifferentiated and
differentiating culture contributes to their differential
sensitivities.Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016 975
Figure 5. Dose-Response Viability and Proliferation Effects of Select Compounds on Undifferentiated and Differentiating ReNcell
VM NPCs
(A) Vehicle control-normalized dose-response viability of undifferentiated (C) and differentiating (D) NPCs plotted against log(con-
centration [mM]). Mean viability ± SEM is plotted for each concentration as determined from 30 biological replicates per dose. Sigmoidal
fits to the data are plotted as solid lines.
(B) Dose-response EdU incorporation of undifferentiated (C, left axis) and differentiating (D, right axis except DOX) NPCs plotted against
log(concentration [mM]). Mean % EdU positive nuclei ± SEM is plotted for each concentration as determined from ten biological replicates.
Dose-response viability and proliferation results for compounds not presented herein are available in Figures S4 and S5.DISCUSSION
There is considerable interest in developing high-through-
put technologies for microscale analysis and screening of
both undifferentiated and differentiated human stem/pro-
genitor populations to aid drug screening and toxicity anal-
ysis (Bhatia and Ingber, 2014; El-Ali et al., 2006). Animal
models are often used to assess toxicity, including neuro-
toxicity, but they are associated with high costs and results
that often have poor translation to humans (DiMasi et al.,
2003; Hay et al., 2014). Human cell-based microarray
screening systems are attractive because of automated
systems for handling liquids that can enable screening
withminimal reagent consumption. This is of particular in-
terest in elucidating the influence of ECM factors and/or
signaling pathways on stem/progenitor function and dif-
ferentiation and to investigate the large combinatorial
space associated with their respective microenvironments.
In the present work, we have demonstrated a chip-based
microarray platform that allows for simple medium ex-
change on microscale 3D cultures. Importantly, on-chip
growth and differentiation of a human progenitor cell
line was possible for more than 2 weeks. In addition, sensi-
tive fluorescence-based assays were compatible to screen976 Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016for protein expression, cytotoxicity, and proliferation.
The system presented herein is advantageous for several
reasons. Miniaturization of 3D cultures, which may better
emulate in vivo conditions, permits investigation under
conditions where diffusional limitations are negligible
(Ranga et al., 2014; Meli et al., 2014). Moreover, the modu-
larity of a system with two complementary chips (one
for cells and one for medium components) that stamp
together to generate the high-throughput cell culture is
potentially suitable for 3D parallel screening. This is funda-
mentally distinct from other high-throughput 3D micro-
scale culture platforms, e.g., in 1536-well plates, where
medium exchange is cumbersome and specialized auto-
mated systems are often optimized for 2D cultures, which
restricts the duration of culture and/or screening (Ranga
et al., 2014).
The growth rate of ReNcell VM cultured on-chip in 3D
Matrigel was roughly three times slower than that reported
for 2D cultures (Donato et al., 2007; Meli et al., 2014). The
on-chip 3D cultures are prepared at a medium-to-cell ratio
that is about half that typically used with larger-scale (i.e.,
flask) 2D cultures. Thus, the relative quantity of available
nutrients as a result of scale-down could contribute to de-
layed growth. In agreement with this, our factorial screen
Table 1. Differential Acute Toxicity Effects on Viability and Proliferation of Undifferentiated and Differentiating ReNcell VM NPCs
Chemical
Viability Effects Proliferation Effects
Undifferentiated Differentiating Undifferentiating Differentiating
log(IC50 ± SEM)
IC50
(mM) log(IC50 ± SEM) IC50 (mM) log(IC50 ± SEM)
IC50
(mM) log(IC50 ± SEM)
IC50
(mM)
Acetaminophena 3.1 ± 0.21 1,400 4.3 ± 0.24 18,000 3.017 ± 0.05 1,000 4.26 ± 0.52 18,200
5-Fluorouracil 0.36 ± 0.31 2.3 0.35 ± 0.22b 2.3 0.14 ± 0.10 1.35 0.26 ± 0.40 1.82
Cytosine Arabinosidec 0.48 ± 0.17b 0.33 0.55 ± 0.55 3.5 < 1 – < 1 –
Retinoic Acida 0.13 ± 0.21 0.74 1.7 ± 1.2 47 1.17 ± 0.11 15 1.35 ± 0.26 22
Doxorubicina 0.1 ± 0.11 0.8 0.44 ± 0.06 2.7 < 1 – < 1 –
Cadmium Chloride 0.57 ± 0.3 3.7 0.88 ± 0.27 7.6 0.93 8.6 1.18 15
Paraquat 1.8 ± 0.18 57 1.61 ± 0.18 41 1.77 ± 0.09 59 1.48 ± 0.64 30
Pitavistatin 0.73 ± 0.16 5.4 – – 0.29 ± 0.07 2.0 0.01 ± 0.39 0.98
Diphenhydramine 2.41 ± 0.37 257 2.3 ± 0.24 189 – – – –
Extracted IC50 values from sigmoidal fits of dose-response viability and proliferation screening displayed as log(IC50 ± SEM [mM]) and corresponding IC50
value (mM). Chemicals which elicited differential effects on undifferentiated and differentiating NPCs are highlighted in bold. Results are based on dose-
response data from which each dose had 30 biological replicates unless indicated. Dose-response data not amenable to sigmoidal fitting are represented as a
dash. Unlisted screened compounds were omitted because the dose-response screen did not capture the effective window, making them unfit for sigmoidal
curve fitting.
ap < 0.05 (two-tailed Student’s t test).
bResults based on data from which each dose had 20 biological replicates.
cp < 0.10 (two-tailed Student’s t test) difference between IC50 of undifferentiated and differentiating NPCs.identified thatmore frequentmedium change led to higher
numbers of viable cells. We reasoned it was unlikely that
diffusional limitations were contributing to slower cellular
growth with our 200 mm cell spots because Ranga
et al. (2014) demonstrated that soluble nutrients rapidly
diffused throughout PEG-based hydrogels of 500 mm in
thickness, while Meli et al. (2012) reported that oxygen
diffusional limitation in 3D microscale cultures was negli-
gible. Nonetheless, crosslinked Matrigel has been reported
to have pore sizes <2 mm, which could result in physical
constraints on cell growth in the encapsulated environ-
ment (Zaman et al., 2006). Thus, the slower growth
observed on-chip could be a result of the need for NPCs
to remodel and/or displace the encapsulating matrix
to accommodate cell growth and cell-cell interactions.
Regardless, conditions that mediate slow growth can be
compatible with stem cell differentiation.
Our observation that the expression of multipotency
markers (SOX2 and NES) persisted in 2D cultures, and
even increased relative to undifferentiated cultures in 3D
after 10 days of differentiation, was of note. Nevertheless,
it has been demonstrated that NES expression decreases
slowly; human midbrain neural progenitors have been
shown to retain NES expression beyond 4 weeks of differ-
entiation both in vitro and in vivo (Sun et al., 2008; Zhang
et al., 2001). However, SOX2 expression is expected todecrease following differentiation into an oligopotent
cell state (Bani-Yaghoub et al., 2006; Graham et al., 2003).
ReNcell VM was immortalized by v-myc gene transduction
of primary fetal neural progenitors. Recently Pino-Barrio
et al. (2015) reported that inducing v-myc expression in
NPCs increases SOX2 expression (Donato et al., 2007).
Therefore, it is possible that overexpression of v-myc im-
pacts the downregulation of SOX2 during differentiation
of ReNcell VM, which could prolong or interfere with
terminal differentiation. However, the downregulation of
SOX2 after a 6-week differentiation suggests that v-myc
immortalization does not inhibit the eventual downregula-
tion of this multipotency marker.
Removal of growth factor-mediated self-renewal signaling
in NPC cultures should result in increased expression of ter-
minal differentiation markers (Graham et al., 2003; Sun
et al., 2008). Indeed, in 2D monolayer cultures, ReNcell
VM increased expression of proteins associated with termi-
nal differentiation into astrocytes, neurons, and oligoden-
drocytes. Other studies have reported similar results with
ReNcell VM after differentiation induced by growth factor
withdrawal in monolayer culture (Donato et al., 2007;
Hoffrogge et al., 2006; Lange et al., 2011), and terminal
neuronal differentiation has been limited without employ-
ing methods aimed at directing neuronal differentiation.
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expressed TUBB3 after 7 days of differentiation induced by
growth factorwithdrawal. In 3DMatrigel, observed changes
in protein marker expression upon differentiation were
notably different compared with 2D cultures, which sug-
gests that Matrigel impacts the spontaneous differentiation
of ReNcell VM. Matrigel is a complex mixture of diverse
ECM components, including proteoglycans, which may
also impact differentiation. In addition, self-renewal growth
factors (EGFand/orFGF2)may remain in the3Dmatrixeven
after their removal from medium due to cytokine-matrix
interactions, which could influence the progression of
NPC differentiation. Indeed, Akashi et al. (2005) observed
reduced diffusion of FGF2 through Matrigel matrices, sug-
gesting that its elimination from the microenvironment
could be delayed.
Moderate increased expression of terminal markers with
retained expression of multipotency markers after 10 days
suggests that spontaneous terminal ReNcell VM differen-
tiation progresses slowly, and this may not be unique. Shi
et al. (2012) reported that terminal differentiation of
iPSC-derived forebrain neural progenitors entailed a 20-
day culture. Furthermore, Choi et al. (2014) reported differ-
entiating ReNcell VM for 6 weeks or longer to derive high
proportions of terminally differentiated cells in 3D Matri-
gel. Thus, long-term differentiation may be required to
obtain a high degree of terminally differentiated neural
cells with ReNcell VM. Nonetheless, while not sub-
stantially terminally differentiated, ReNcell VM cultured
without growth factors for 10 days were distinct from those
grown in the presence of EGF and FGF2 and are likely a
mixture of NPCs at various stages of differentiation.
Of the 16 compounds that substantially decreased
viability, seven had IC50 concentrations <100 mM. This
included acutely toxic compounds (e.g., paraquat, CdCl2)
with IC50 values consistent with literature values (Breier
et al., 2008). Compounds without potent neurotoxicity
(e.g., acetaminophen, caffeine, diphenhydramine) were
found to have no cytotoxicity at functionally relevant con-
centrations, and only at concentrations associated with
systemic human toxicity did decreases in viability occur
(Brent et al., 2011; Clemedson et al., 2007; Radovanovic
et al., 2000). PbCl2 and MnCl2 did not reduce cell viability
for either undifferentiated or differentiating cultures. Their
neurotoxicity is associated with complex mechanisms that
often do not manifest as acute cytotoxicity (Neal and Gui-
larte, 2013). Taken together, these results begin to define
the utility of the immortalized ReNcell VM for assessing
chemical neurotoxicity.
Five compounds elicited differential effects on undif-
ferentiated and differentiating NPCs. All-trans retinoic
acid is an important endogenous neurodevelopmental
signaling small molecule that can also act as a develop-
mental teratogen when dysregulated (Lammer et al.,978 Stem Cell Reports j Vol. 7 j 970–982 j November 8, 20161985; McCaffery et al., 2003), and undifferentiated NPCs
exhibited a lower IC50 in response to retinoic acid versus
differentiating NPCs. In addition, retinoic acid increased
the average number of proliferating cells within differ-
entiated cultures by greater than 3-fold at lower concen-
trations. Notably, the neurodevelopmental effects and
sensitivity of rats to retinoic acid has previously been found
to be dependent on the concentration and onset of expo-
sure (McCaffery et al., 2003). As highlighted above, the
acetaminophen concentrations needed to observe toxicity
were above those that would be pharmacologically effec-
tive, although a large difference in sensitivity was observed
between undifferentiated and differentiating cultures.
Pitavastatin, a 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HmG-CoA) reductase inhibitor, was cytotoxic only to un-
differentiated NPCs, whereas another HmG-CoA reductase
inhibitor, cilastatin, had no effect. Similarly, 5-FU was
substantially more toxic to undifferentiated cultures and
resulted in nearly complete killing while minimally im-
pacting differentiating cultures. Both drugswere also found
to inhibit the proliferation of NPC cultures, which suggests
that the mechanism of toxicity was predominantly anti-
proliferative (in agreement with their known mechanisms
of toxicity) because they did not decrease the viability
of slowly proliferating differentiating NPCs (Chan et al.,
2003; Diasio and Harris, 1989). The observation that pita-
vastatin inhibited proliferation and that cilastatin did not
is consistent with the finding of Chan et al. (2003) that
statins have highly variable anti-proliferative effects on
various cell lines and cancers.
DOX and CA are well-known chemotherapeutics with
anti-proliferative and cytotoxic activity (Gewirtz, 1999;
Momparler, 1982). For undifferentiated NPCs, DOX gave
lower NPC viability (lower IC50), and to a lesser extent so
did CA (p < 0.10), in comparison with differentiating
NPCs. Because 3% of differentiating NPCs actively prolif-
erated, the effects of DOX and CA suggest that cytotoxicity
was the predominant mechanism of killing differentiating
NPCs. This result also suggests that undifferentiated NPCs
may be more sensitive to these compounds as a result of
both anti-proliferative and cytotoxic mechanisms being
effective against the undifferentiated, highly proliferative
cell state.
The results presented herein demonstrate the application
of a microarray chip platform as a sensitive screening tool
capable of detecting differential toxicities of biologically
active compounds in humanNPCs of varied levels of differ-
entiation. Given the need to develop in vitro screening
platforms that can assess the activity and toxicity of chem-
icals on human cells, the chip platform may serve as a 3D
phenotypic screening tool to better predict toxicity of, or
identify, bioactive compounds in human stem/progenitor
cells. Further research on non-immortalized NPCs may
provide useful insights into the influence of specific com-
pounds on stem cells and their progeny of various fates.EXPERIMENTAL PROCEDURES
Human Neural Progenitor Cell Culture
ReNcell VM (Millipore) was used in this study at passage number
16 or lower. Cells were grown on laminin (Sigma)-coated T25 or
T75 tissue-culture-treated flasks in complete growth medium
composed of ReNcellMaintenanceMedium (Millipore) containing
20 ng/mL FGF2 (Millipore), 20 ng/mL EGF (Millipore), and 1%
(v/v) penicillin-streptomycin (Gibco). Cells were passaged using
Accutase and re-plated at 10,000 cells/cm2 when 90% confluent.
Medium was changed the day after passaging and every second
day after that. For off-chip 3D culture, ReNcell VM were seeded
at 890,000 cells/mL in 100 mL of 1% Matrigel in 8-well chamber
microscope slides (Nunc) with daily medium change. All cultures
were maintained at 37C and 5% CO2.3D Microarray Culture Preparation
Polystyrene micropillar and microwell chips (SEMCO) were
exposed to UV (302 nm) light (9 cm from source) for 4 hr using a
96-W transilluminator (Syngene GVM-30), following a similar
procedure to that of Kohen et al. (2009), which helped maintain
the cell spots atop the micropillars without covalent attachment.
An enclosed MicroSys 5100-4SQ (DigiLab) non-contact robotic
microarray spotting system was used for printing. During opera-
tion, the relative humidity was maintained above 95% to reduce
evaporation. The MicroSys 5100-4SQ spotting head was modified
with two water-block assemblies for circulation of chilled ethylene
glycol-water to maintain the printer head between 2 and 8C
during Matrigel spotting.
To prepare microarray cultures, 850 nL of complete growth me-
dium was printed into WellChips and covered with gas-permeable
sealingmembranes (DiversifiedBiotech) and stored in an incubator
(37C and 5% CO2). High-concentration growth factor-reduced
Matrigel (Corning Life Sciences) was used for 1% (w/v) encapsula-
tion and growth factor-reduced phenol red-free Matrigel (Corning
Life Sciences) was used for 0.5% (w/v) encapsulation. Cooled sus-
pensions of newly passaged ReNcell VMwere mixed with Matrigel
in a ratio such that thefinal cell concentrationwas33106 cells/mL,
unless otherwisenoted,withfinalMatrigel concentrationsof either
0.5% or 1% (w/v) and stored on ice until printing. The cooled mi-
croarray system was used to print the Matrigel-cell mixtures onto
PillarChips (300 cells within each spot). Following printing, the
PillarChips were incubated 4 min at 25C followed by 10 min at
37C in a humid chamber to polymerize the Matrigel. After gela-
tion, a PillarChipwas stamped into aWellChip containingwarmed
complete growth medium and stored in a humidified chamber for
culture. Themediumwas changeddailyunless otherwisenoted. Pe-
riphery wells were not analyzed to prevent potential evaporation
from affecting the results.Live/Dead Viability Assay
Cell viability was determined in 3D on-chip cultures using a
mammalian cell viability assay (LIVE/DEAD, Invitrogen). Prior tothe assay, dead cell controls were prepared with 30min incubation
in a WellChip containing either complete medium or 0.5% (w/v)
saponin-DMEM/F12 medium in its microwells. PillarChips were
rinsed twice with warm DPBS and incubated for 25 min in DPBS
with 1 g/L glucose, 4 mM calcein-AM, 2 mM ethidium homo-
dimer-I, and 5 mg/mL Hoechst 33342 at 5% CO2 and 37
C. After
staining, PillarChips were rinsed twice with warm DPBS and incu-
bated in DPBS containing 50 mM trehalose (Sigma) for 10 min
before rapid drying with nitrogen and storage in the dark. Dried
PillarChips were imaged with a Thermo Scientific Cellomics
ArrayScan VTI high-content system.In-Cell Immunofluorescence Assays
Undifferentiated NPCs were plated on laminin-coated 96-well
plates and cultured for 3 days in complete growth medium prior
to fixation. Differentiated NPCs were prepared by expanding un-
differentiated NPCs for 3 days, followed by differentiation in
medium without EGF and FGF2 for 10 days with daily medium
change to emulate on-chip conditions. Cells were rinsed with
warm DPBS and fixed with 4% (w/v) formaldehyde and 0.25%
(w/v) glutaraldehyde in DPBS for 20 min at room temperature.
Fixed cells were permeated with 0.25% (v/v) Triton X-100 in
DPBS for 10 min, rinsed with DPBS, and quenched for 30 min in
DPBS with 2 mg/mL sodium borohydride (Sigma). Cells were
blocked overnight at 4C in DPBS with 5% (w/v) BSA and 1%
(v/v) goat serum and incubated in primary antibody solutions
diluted into DPBS containing 1% (w/v) BSA and 10 ppm anti-
foamC (Sigma) overnight at 4C. Samples werewashed three times
with DPBS for 2 hr before repeating the antibody incubation step
for secondary antibodies. A complete list of primary and secondary
antibodies, vendors, and dilutions used is presented in Table S1. Af-
ter incubation with secondary antibodies, samples were washed
three times with DPBS for 2 hr before 10 min incubation in
DPBS with 5 mg/mL Hoechst 33342 and a final rinse with DPBS.
An inverted fluorescent microscope was used for imaging and
ImageJ was used to process images.
On-chip undifferentiated NPCs were analyzed after 5 days
and differentiated cells after a 10-day differentiation following
a 5-day expansion. Antibody incubations were performed in
750 nL of antibody containing solutions on-chip. After the final
washes, PillarChips were rinsed with DPBS containing 50 mM
trehalose for 10 min before being completely dried with nitrogen
and stored in the dark. Dried PillarChips were imaged using a
Thermo Scientific Cellomics ArrayScan VTI high-content system.
Control cell spots incubated solely with fluorescently labeled sec-
ondary antibodies yielded low, non-specific background signals
that were subtracted during analysis.Western Blotting
Protein concentration of lysates was estimated using a BCA assay
(Sigma). Equal amounts of protein (10 mg) were loaded into either
8%or 12% cast SDS-PAGE gels. Gelswere resolved at 120V in a Tris-
glycine buffer and electrotransferred to a nitrocellulose membrane
for either 60 min at 100 V (12% gel) or overnight at 30 V (8% gel)
at 4C. Membranes were rinsed with Tris-buffered saline (TBS),
blocked in 5% (w/v) BSA TBS for 1 hr at room temperature, and
incubated overnight at 4C in primary antibody solutions dilutedStem Cell Reports j Vol. 7 j 970–982 j November 8, 2016 979
in blocking buffer with 0.05% (v/v) Tween 20. Membranes were
rinsed with TBS containing 0.05% Tween 20 (TBST) and incubated
with an appropriate secondary antibody diluted in TBS with 3%
BSA for 90 min at room temperature. Membranes were washed
with TBST and then TBS before incubation with chemilumines-
cence solution (SuperSignal Pico, Pierce) for 10 min. Membranes
were imaged with a Bio-Rad ChemiDoc and subsequently stripped
using a stripping buffer (200mMglycine, 1% [v/v] Tween 20, 0.1%
[w/v] SDS [pH 2]) and evaluated for efficient stripping with chem-
iluminescence before being reused with the above procedure for
detection of loading control proteins (GAPDH for 12% gels, vincu-
lin for 8% gels).On-Chip Cytotoxicity Assay
Undifferentiated and differentiated microchip cultures were pre-
pared as described above. Chemicals were purchased from Sigma
or the NIH Small Molecule Repository (Table S2). Concentrated
stocks were prepared and diluted into ReNcell Maintenance Me-
dium to prepare the highest screened concentration solution for
each compound. Four-fold serial dilutions were made in ReNcell
Maintenance Medium, with all solutions having a final concentra-
tion of 0.5% or 1% DMSO (v/v) and 20 mg/mL Matrigel. For undif-
ferentiated cultures, the solutions also contained 20 ng/mL of EGF
and FGF2. These solutions were printed into WellChips, covered
with a gas-permeable membrane, and warmed at 37C for at least
5 min before stamping with cells. Each WellChip contained six
compounds each at six concentrations (n = 10 biological replicates
for each concentration) and the appropriate medium containing
0.5% or 1% DMSO for vehicle and dead controls (n = 32 biological
replicates per control). PillarChip cultures were incubated with
compounds for 72 hr with daily medium exchange to freshly pre-
pared WellChips containing compounds at the appropriate con-
centrations. After 72 hr, PillarChips were assayed with the viability
assay and when appropriate data were fit to a sigmoidal dose-
responsemodelusingGraphPadPrismfor IC50 calculation (see Sup-
plemental Information). On-chip toxicity screens were repeated
three times for undifferentiated and differentiated cultures.On-Chip Proliferation Assay
Undifferentiated and differentiating cultures were screened for
toxicity as described previously, except that after the first 48 hr
of exposure 10 mM EdU (Click-iT EdU, Invitrogen) was added to
the compound-containing medium for the final 24 hr. After
72 hr, on-chip cultures were fixed and processed as described
previously for on-chip immunofluorescence; however, instead of
antibody staining the cultures were incubated with solution con-
taining Alexa Fluor 488-azide for 30min as specified in the product
manual. Cultures were then rinsed with DPBS for 30 min, incu-
bated in DPBS with Hoechst 33342 (5 mg/mL) for 30 min, and
washed in DPBS for 30 min before proceeding with a trehalose
wash and drying as described previously. Nuclei were selected
using Cellomics software from blue channel images to create a
mask, which was used for identification of fluorescently labeled
EdU in the green channel for quantification of actively prolifer-
ating cells over the 24-hr EdU exposure. Datawere fit to a sigmoidal
dose-response model using GraphPad Prism to calculate IC50
values.980 Stem Cell Reports j Vol. 7 j 970–982 j November 8, 2016SUPPLEMENTAL INFORMATION
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